IMP761, an experimental immunosuppressive therapy being developed by Immutep for multiple sclerosis (MS) and other autoimmune diseases, was well tolerated in healthy volunteers when given at single increasing doses. The findings come from the single-ascending dose portion of an ongoing Phase 1 clinical trial (NCT06637865),…
An experimental therapy designed to eliminate harmful B-cells — key drivers of inflammation in multiple sclerosis (MS) and other autoimmune diseases — has reached an early development milestone. The treatment candidate, CDR111, is being developed under a collaboration between CDR-Life and Boehringer Ingelheim. The milestone…
By Dr. Eva Jackson The Power of Advocacy Sherry Lee Mueller once wrote that advocacy is the art of building relationships. In our MS community, advocacy empowers change, strengthens our community, and gives a voice to those who may have … Continue reading → Source:…
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like…
When Brenda Snow started experiencing vertigo, vision problems, and other symptoms in the early 1990s, she visited several doctors. However, as often happens with complex conditions, she struggled to have her concerns validated. Snow, who lived in Northern California at the time, didn’t give up.…
Tweet Artificial intelligence is putting humans onto the maggots pile. I don’t know if you have had the same experience but AI has replaced customer service which is all well and dandy when the questions you have are easy but if you are having a…
The post From our CEO appeared first on MS Australia. Source: www.msaustralia.org.au